|
1
|
Guo M, Zhao YD, Yang HJ and Yan XF:
Analysis of clinicopathological characteristics for 5406 cases of
esophageal neoplasm. Chin J Cancer Prev Treat. 15:54–56. 2008.
|
|
2
|
Debevec L, Jeric T, Kovac V, et al: Is
there any progress in routine management of lung cancer patients? A
comparative analysis of an institution in 1996 and 2006. Radiol
Oncol. 43:47–53. 2009. View Article : Google Scholar
|
|
3
|
Kovac V, Zwitter M and Zagar T:
Population-based survey of malignant pleural mesothelioma in
Slovenia: improved survival after introduction of chemotherapy.
Radiol Oncol. 46:136–144. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Law SY, Fok M and Wong J: Pattern of
recurrence after oesophageal resection for cancer: clinical
implications. Br J Surg. 83:107–111. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bhansali MS, Fujita H, Kakegawa T, et al:
Pattern of recurrence after extended radical esophagectomy with
three-field lymph node dissection for squamous cell carcinoma in
the thoracic esophagus. World J Surg. 21:275–281. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Osugi H, Takemura M, Takada N, et al:
Prognostic factors after esophagectomy and extended lymphadenectomy
for squamous esophageal cancer. Br J Surg. 89:909–913. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rice TW, Rusch VW, Ishwaran H, et al;
Worldwide Esophageal Cancer Collaboration: Cancer of the esophagus
and esophagogastric junction: data-driven staging for the seventh
edition of the American Joint Committee on Cancer/International
Union Against Cancer Staging Manuals. Cancer. 116:3763–3773. 2010.
View Article : Google Scholar
|
|
8
|
Dresner SM and Griffin SM: Pattern of
recurrence following radical esophagectomy with two-field
lymphadenectomy. Br J Surg. 87:1426–1433. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Isono K, Sato H and Nakayama K: Results of
a nationwide study on the three-field lymph node dissection of
esophageal cancer. Oncology. 48:411–420. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dixit S, Tilston M and Peter WM: Risk
stratification for recurrence in patients with esophageal and
junctional carcinoma treated with neoadjuvant chemotherapy and
surgery. Med Oncol. 27:242–248. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Matsubara T, Ueda M, Nagao N, et al:
Cervicothoracic approach for total mesesophageal dissection in
cancer of the thoracic esophagus. J Am Coll Surg. 187:238–245.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Altorki NK and Skinner DB: Occult cervical
nodal metastasis in esophageal cancer: preliminary results of
three-field lymphadenectomy. J Thorac Cardiovasc Surg. 113:540–544.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shiozaki H, Yano M, Tsujinaka T, et al:
Lymph node metastasis along the recurrent nerve chain is indication
for cervical lymph node dissection in thoracic esophageal cancer.
Dis Esophagus. 14:191–196. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen J, Liu S, Pan J, et al: The pattern
and prevalence of lymphatic spread in thoracic oesophageal squamous
cell carcinoma. Eur J Cardiothorac Surg. 36:480–486. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ando N, Iizuka T, Ide H, et al; Japan
Clinical Oncology Group: Surgery plus chemotherapy compared with
surgery alone for localized squamous cell carcinoma of the thoracic
esophagus: a Japan Clinical Oncology Group Study - JCOG9204. J Clin
Oncol. 21:4592–4596. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pouliquen X, Levard H, Hay JM, et al:
5-Fluorouracil and cisplatin therapy after palliative surgical
resection of squamous cell carcinoma of the esophagus. A
multicenter randomized trial French Associations for Surgical
Research. Ann Surg. 223:127–133. 1996. View Article : Google Scholar
|
|
17
|
Lee J, Lee KE, Im YH, et al: Adjuvant
chemotherapy with 5-fluorouracil and cisplatin in lymph
node-positive thoracic esophageal squamous cell carcinoma. Ann
Thorac Surg. 80:1170–1175. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Heroor A, Fujita H, Sueyoshi S, et al:
Adjuvant chemotherapy after radical resection of squamous cell
carcinoma in the thoracic esophagus: who benefits? A retrospective
study. Dig Surg. 20:229–235; discussion. 236–237. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shiozaki A, Yamagishi H, Itoi H, et al:
Long-term administration of low-dose cisplatin plus 5-fluorouracil
prolongs the postoperative survival of patients with esophageal
cancer. Oncol Rep. 13:667–672. 2005.PubMed/NCBI
|
|
20
|
Bystricky B, Okines AF and Cunningham D:
Optimal therapeutic strategies for resectable oesophageal or
oesophagogastric junction cancer. Drugs. 71:541–555. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang J, Chen HQ, Zhang YW, et al:
Adjuvant chemotherapy in oesophageal cancer: a meta-analysis and
experience from the Shanghai Cancer Hospital. J Int Med Res.
36:875–882. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lu JC, Qian PD, Zha WW, et al: The
meta-analysis of randomized controlled trial of prophylactic
radiotherapy for esophageal carcinoma after curative resection. J
Evid Based Med. 5:166–171. 2005.
|
|
23
|
Macdonald JS, Smalley SR, Benedetti J, et
al: Chemoradiotherapy after surgery compared with surgery alone for
adenocarcinoma of the stomach or gastroesophageal junction. N Engl
J Med. 345:725–730. 2001. View Article : Google Scholar
|
|
24
|
Gaast AV, van Hagen P, Hulshof M, et al:
Esophagogastric junction cancer: Results from a multicenter
randomized phase III study. J Clin Oncol (Meeting Abstracts).
28:40042010.
|
